Evidence map›Paper›PMID 41438365›Full record

ArticleMolecular therapy. Nucleic acids2025

The role of exosomes as oligonucleotide delivery system for managing α-synuclein in Parkinson's disease: A systematic review of

Soodeh Salarpour, Fatemeh Dourandish, Arsalan Salajegheh, Sara Hashemi

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular therapy. Nucleic acids, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Soodeh SalarpourPharmaceutics Research Center, Institute of Neuropharmacology, Kerman University of Medical Sciences, Kerman 7616911320, Iran.
Fatemeh DourandishDepartment of Medical Chemistry, Faculty of Pharmacy, Kerman University of Medical Sciences, Kerman 7616911320, Iran.
Arsalan SalajeghehResearch and Development Center, Food and Drug Administration, Kerman University of Medical Sciences, Kerman 7616911320, Iran.
Sara HashemiPharmaceutics Research Center, Institute of Neuropharmacology, Kerman University of Medical Sciences, Kerman 7616911320, Iran.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Although Parkinson's disease (PD) is primarily idiopathic, genetic mutations-accounting for approximately 5%-15% of cases with regional variability-have prompted the development of gene expression modulators, such as oligonucleotides, to target and reduce alpha-synuclein (α-syn) accumulation. However, challenges in delivering these agents to the brain have limited their therapeutic potential. This study systematically reviews the use of exosomes as delivery systems for oligonucleotides aimed at reducing α-syn aggregation in PD. A comprehensive literature search was conducted using Scopus, Embase, OVID, and ISI Web of Science databases up to January 2022, targeting

Indexed as

alpha-synucleinantisense oligonucleotidesblood–brain barrier targetingexosomeextracellular vesiclesgene therapyMTneurodegenerationoligonucleotide deliveryOligonucleotidesParkinson’s diseaseTherapies and Applications

Identifiers

PMID41438365
PMCPMC12719085

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.